{"id":19679,"date":"2022-06-27T08:15:39","date_gmt":"2022-06-27T15:15:39","guid":{"rendered":"https:\/\/marketdepth.com\/?p=19679"},"modified":"2022-06-27T08:15:41","modified_gmt":"2022-06-27T15:15:41","slug":"hillstream-biopharma-partners-with-sapien-biosciences","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/hillstream-biopharma-partners-with-sapien-biosciences\/","title":{"rendered":"Hillstream BioPharma Partners with Sapien Biosciences"},"content":{"rendered":"\n
Hillstream BioPharma, Inc. (Nasdaq: HILS)<\/strong> today announced that it has begun a collaboration with Sapien Biosciences to evaluate the synergy of HSB-1216 with immune checkpoint inhibitors.<\/p>\n\n\n\n \u201cWe are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody.\u201d<\/p>Randy Milby, Hillstream\u2019s Chief Executive Officer<\/cite><\/blockquote>\n\n\n\n Treatment with immune checkpoint inhibitors (ICIs) induces the effector function of T cells in the tumor microenvironment (TME). Activated T cells accumulated in TME then kill tumor cells mainly by enhancing cell death through the granzyme pathway and by releasing interferon gamma (IFN) from CD8+ T cells, according to the press release.<\/p>\n\n\n\n \u201cWe are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology. Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.\u201d<\/p>Dr. Jugnu Jain, CEO, Sapien Biosciences<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"Hillstream BioPharma, Inc. (Nasdaq: HILS) today announced that it has begun a collaboration with Sapien Biosciences to evaluate the synergy of HSB-1216 with immune checkpoint inhibitors. \u201cWe are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody.\u201d Randy Milby, Hillstream\u2019s Chief Executive Officer… View Article<\/a>","protected":false},"author":3,"featured_media":18750,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,10,8,11,16],"tags":[],"acf":[],"yoast_head":"\n